CPC A61K 47/6849 (2017.08) [A61K 47/6813 (2017.08); A61K 47/6817 (2017.08); A61K 47/6851 (2017.08); C07K 16/2827 (2013.01)] | 22 Claims |
1. A antibody conjugate represented by Formula I or pharmaceutically acceptable salt or solvate thereof:
Ab-(G)n Formula I
wherein:
Ab is an anti-B7-H3 antibody or antigen-binding fragment thereof comprising a variable heavy chain complementarity determining region 1 (CDRH1), a variable heavy chain complementarity determining region 2 (CDRH2), a variable heavy chain complementarity determining region 3 (CDRH3), a variable light chain complementarity determining region 1 (CDRL1), a variable light chain complementarity determining region 2 (CDRL2), and a variable light chain complementarity determining region 3 (CDRL3); wherein,
CDRH1 comprises an amino acid sequence of SEQ ID NO: 1,
CDRH2 comprises an amino acid sequence of SEQ ID NO: 2,
CDRH3 comprises an amino acid sequence of SEQ ID NO: 3,
CDRL1 comprises an amino acid sequence of SEQ ID NO: 4,
CDRL2 comprises an amino acid sequence of SEQ ID NO: 5, and
CDRL3 comprises an amino acid sequence of SEQ ID NO: 6; or
CDRH1 comprises an amino acid sequence of SEQ ID NO: 7,
CDRH2 comprises an amino acid sequence of SEQ ID NO: 8,
CDRH3 comprises an amino acid sequence of SEQ ID NO: 9,
CDRL1 comprises an amino acid sequence of SEQ ID NO: 10,
CDRL2 comprises an amino acid sequence of SEQ ID NO: 11, and
CDRL3 comprises an amino acid sequence of SEQ ID NO: 12; or
CDRH1 comprises an amino acid sequence of SEQ ID NO: 13,
CDRH2 comprises an amino acid sequence of SEQ ID NO: 14,
CDRH3 comprises an amino acid sequence of SEQ ID NO: 15,
CDRL1 comprises an amino acid sequence of SEQ ID NO: 16,
CDRL2 comprises an amino acid sequence of SEQ ID NO: 17, and
CDRL3 comprises an amino acid sequence of SEQ ID NO: 18; or
CDRH1 comprises an amino acid sequence of SEQ ID NO: 19,
CDRH2 comprises an amino acid sequence of SEQ ID NO: 20,
CDRH3 comprises an amino acid sequence of SEQ ID NO: 21,
CDRL1 comprises an amino acid sequence of SEQ ID NO: 22,
CDRL2 comprises an amino acid sequence of SEQ ID NO: 23, and
CDRL3 comprises an amino acid sequence of SEQ ID NO: 24; or
CDRH1 comprises an amino acid sequence of SEQ ID NO: 25,
CDRH2 comprises an amino acid sequence of SEQ ID NO: 26,
CDRH3 comprises an amino acid sequence of SEQ ID NO: 27,
CDRL1 comprises an amino acid sequence of SEQ ID NO: 28,
CDRL2 comprises an amino acid sequence of SEQ ID NO: 29, and
CDRL3 comprises an amino acid sequence of SEQ ID NO: 30; or
CDRH1 comprises an amino acid sequence of SEQ ID NO: 31,
CDRH2 comprises an amino acid sequence of SEQ ID NO: 32,
CDRH3 comprises an amino acid sequence of SEQ ID NO: 33,
CDRL1 comprises an amino acid sequence of SEQ ID NO: 34,
CDRL2 comprises an amino acid sequence of SEQ ID NO: 35, and
CDRL3 comprises an amino acid sequence of SEQ ID NO: 36; or
CDRH1 comprises an amino acid sequence of SEQ ID NO: 37,
CDRH2 comprises an amino acid sequence of SEQ ID NO: 38,
CDRH3 comprises an amino acid sequence of SEQ ID NO: 39,
CDRL1 comprises an amino acid sequence of SEQ ID NO: 40,
CDRL2 comprises an amino acid sequence of SEQ ID NO: 41, and
CDRL3 comprises an amino acid sequence of SEQ ID NO: 42; or
CDRH1 comprises an amino acid sequence of SEQ ID NO: 43,
CDRH2 comprises an amino acid sequence of SEQ ID NO: 44,
CDRH3 comprises an amino acid sequence of SEQ ID NO: 45,
CDRL1 comprises an amino acid sequence of SEQ ID NO: 46,
CDRL2 comprises an amino acid sequence of SEQ ID NO: 47,
CDRL3 comprises an amino acid sequence of SEQ ID NO: 48;
and further wherein:
each G is, independently, a chemical moiety comprising one or more active agents and a linker, wherein the linker links Ab to the active agent(s); and
n is an integer between 1 to 20.
|